Androgenetic Alopecia - Pipeline Insight, 2024

Androgenetic Alopecia - Pipeline Insight, 2024

DelveInsight’s, “Androgenetic Alopecia – Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Androgenetic Alopecia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Androgenetic Alopecia Understanding

Androgenetic Alopecia: Overview

Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic ""M"" shape. Pattern or androgenetic alopecia is a genetically predetermined disorder due to excessive response to androgens which affects up to 50% of males and females. It is characterized by progressive loss of terminal hair of the scalp any time after puberty, in a characteristic distribution in both males and females. In males, hair loss is most prominent in the vertex and frontotemporal regions, while in women the frontal hairline is typically spared with diffuse apical hair loss noted as a wider anterior part of the hair. Androgenetic alopecia patients have higher production of dihydrotestosterone, and higher levels of 5 alpha-reductase and androgen receptors in balding scalp. Androgenetic alopecia is usually diagnosed clinically with a history of gradual onset, occurring after puberty, and often but not necessarily, a family history of baldness. There are two FDA approved drugs for pattern baldness: topical minoxidil and finasteride, both of which require at least a 4- to 6-month trial before noticing improvement and must be used indefinitely to maintain a response.

""Androgenetic Alopecia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Androgenetic Alopecia pipeline landscape is provided which includes the disease overview and Androgenetic Alopecia treatment guidelines. The assessment part of the report embraces, in depth Androgenetic Alopecia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Androgenetic Alopecia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Androgenetic Alopecia R&D. The therapies under development are focused on novel approaches to treat/improve Androgenetic Alopecia.

Androgenetic Alopecia Emerging Drugs Chapters

This segment of the Androgenetic Alopecia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Androgenetic Alopecia Emerging Drugs

• KX-826: Kintor Pharma

KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. For the AGA indication, on 8 September 2021, Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile. On 11 July 2021, Kintor Pharma announced that the Food and Drug Administration of the United States greenlighted KX-826's phase II clinical trial for AGA to be conducted in the United States.

• Clascoterone: Cassiopea

Clascoterone solution 7.5% is a novel AR inhibitor that targets androgen receptors in the scalp and is currently being studied for the treatment of androgenetic alopecia (AGA). Clascoterone solution 7.5% acts by inhibiting DHT’s binding with androgen receptors in scalp hair follicles and thus may interfere with DHT’s effect on scalp hair loss. A Phase II dose ranging study with clascoterone solution in males ended in early 2019. Clascoterone solution 7.5% was selected as the best candidate for the Phase III adult male AGA program. A Phase II study involving female AGA subjects is underway with top-line results expected 3Q 2021.

Further product details are provided in the report……..

Androgenetic Alopecia: Therapeutic Assessment

This segment of the report provides insights about the different Androgenetic Alopecia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Androgenetic Alopecia

There are approx. 12+ key companies which are developing the therapies for Androgenetic Alopecia. The companies which have their Androgenetic Alopecia drug candidates in the most advanced stage, i.e. Phase II include, Kintor Pharma.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Androgenetic Alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Androgenetic Alopecia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Androgenetic Alopecia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Androgenetic Alopecia drugs.

Androgenetic Alopecia Report Insights

• Androgenetic Alopecia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Androgenetic Alopecia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Androgenetic Alopecia drugs?
• How many Androgenetic Alopecia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Androgenetic Alopecia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Androgenetic Alopecia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Androgenetic Alopecia and their status?
• What are the key designations that have been granted to the emerging drugs?